Noninvasive modalities exhibit limited diagnostic performance for evaluating the severity of nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) serve as useful biomarkers for diagnosing and monitoring disease progression and treatment response. Here, we evaluated whether serum exosomal miRNAs can be used to clinically predict the severity of NAFLD. Exosomal miRNAs were isolated from the sera of 41 NAFLD patients (diagnosed using biopsy) for array profiling. To compare differentially expressed miRNAs, the degree of severity was determined using inflammation, steatosis, ballooning, and NAFLD activity score (NAS). The correlation of miRNAs with clinical and biochemical parameters was analyzed. The correlation between miRNA and mRNA expression was analyzed by comparing our miRNA expression data with publicly available mRNA expression data. Twenty-five, eleven, thirteen, and fourteen miRNAs correlated with inflammation score, steatosis score, ballooning score, and NAS, respectively. Thirty-three significant correlations were observed between twenty-seven miRNAs and six clinical variables (age, ALP, AST, ALT, GGT, and NAS). In fibrosis, 52 and 30 interactions corresponding to high miRNA-low mRNA and low miRNA-high mRNA expression, respectively, were observed. We demonstrated that serum exosomal miRNAs can be used to evaluate NAFLD severity and also delineate potential targets for NAFLD treatment.
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Posted 05 Jan, 2021
On 11 Mar, 2021
On 27 Feb, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
Invitations sent on 06 Jan, 2021
On 06 Jan, 2021
On 31 Dec, 2020
On 31 Dec, 2020
On 22 Dec, 2020
Posted 05 Jan, 2021
On 11 Mar, 2021
On 27 Feb, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
Received 26 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
On 06 Jan, 2021
Invitations sent on 06 Jan, 2021
On 06 Jan, 2021
On 31 Dec, 2020
On 31 Dec, 2020
On 22 Dec, 2020
Noninvasive modalities exhibit limited diagnostic performance for evaluating the severity of nonalcoholic fatty liver disease (NAFLD). MicroRNAs (miRNAs) serve as useful biomarkers for diagnosing and monitoring disease progression and treatment response. Here, we evaluated whether serum exosomal miRNAs can be used to clinically predict the severity of NAFLD. Exosomal miRNAs were isolated from the sera of 41 NAFLD patients (diagnosed using biopsy) for array profiling. To compare differentially expressed miRNAs, the degree of severity was determined using inflammation, steatosis, ballooning, and NAFLD activity score (NAS). The correlation of miRNAs with clinical and biochemical parameters was analyzed. The correlation between miRNA and mRNA expression was analyzed by comparing our miRNA expression data with publicly available mRNA expression data. Twenty-five, eleven, thirteen, and fourteen miRNAs correlated with inflammation score, steatosis score, ballooning score, and NAS, respectively. Thirty-three significant correlations were observed between twenty-seven miRNAs and six clinical variables (age, ALP, AST, ALT, GGT, and NAS). In fibrosis, 52 and 30 interactions corresponding to high miRNA-low mRNA and low miRNA-high mRNA expression, respectively, were observed. We demonstrated that serum exosomal miRNAs can be used to evaluate NAFLD severity and also delineate potential targets for NAFLD treatment.
Figure 1
Figure 2
Figure 3
Figure 4
Loading...